Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis
Journal of Pharmaceutical Analysis · 2024-05 · 14 (5) · 100904
DOI: 10.1016/j.jpha.2023.11.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2024-05. Verfasst von Binlong Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Center, The Third Xiangya Hospital, Central South University, Changsha, 410013, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Due to the non-targeted release and low solubility of anti-gastric cancer agent, apatinib (Apa), a first-line drug with long-term usage in a high dosage often induces multi-drug resistance and causes serious side effects. In order to avoid these drawbacks, lipid-film-coated Prussian blue nanoparticles (PB NPs) with hyaluronan (HA) modification was used for Apa loading to improve its solubility and targeting ability. Furthermore, anti-tumor compound of gamabufotalin (CS-6) was selected as a partner of Apa with reducing dosage for combinational gastric therapy. Thus, HA-Apa-Lip@PB-CS-6 NPs were constructed to synchronously transport the two drugs into tumor tissue. In vitro assay indicated that HA-Apa-Lip@PB-CS-6 NPs can synergistically inhibit proliferation and invasion/metastasis of BGC-823 cells via downregulating vascular endothelial growth factor receptor (VEGFR) and matrix metalloproteinase-9 (MMP-9). In vivo assay demonstrated strongest anti-tumor growth and liver metastasis of HA-Apa-Lip@PB-CS-6 NPs administration in BGC-823 cells-bearing mice compared with other groups due to the excellent penetration in tumor tissues and outstanding synergistic effects. In summary, we have successfully developed a new nanocomplexes for synchronous Apa/CS-6 delivery and synergistic gastric cancer (GC) therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Management Center, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
- Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
- Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
- College of Biology, Hunan University, Changsha, 410082, China.
Zitieren
APA
Chen, B., Zhao, Y., Lin, Z., Liang, J., Fan, J., Huang, Y., He, L., & Liu, B. (2024). Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis. Journal of Pharmaceutical Analysis, 14(5), 100904. https://doi.org/10.1016/j.jpha.2023.11.011
Vancouver
Chen B, Zhao Y, Lin Z, Liang J, Fan J, Huang Y, et al. Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis. Journal of Pharmaceutical Analysis. 2024;14(5):100904. doi:10.1016/j.jpha.2023.11.011
BibTeX
@article{Chen2024,
author = {Chen, Binlong and Zhao, Yanzhong and Lin, Zichang and Liang, Jiahao and Fan, Jialong and Huang, Yanyan and He, Leye and Liu, Bin},
title = {Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis},
journal = {Journal of Pharmaceutical Analysis},
year = {2024},
volume = {14},
number = {5},
pages = {100904},
doi = {10.1016/j.jpha.2023.11.011}
}
EUVIMED